

# Characteristics and Medium-term Outcomes of Takayasu Arteritis–related Renal Artery Stenosis: Analysis of a Large Chinese Cohort

Ying Sun<sup>1</sup>, Xiaomin Dai<sup>1</sup>, Peng Lv<sup>2</sup>, Zhihui Dong<sup>3</sup>, Lingying Ma<sup>1</sup>, Yan Yan<sup>1</sup>, Jiang Lin<sup>2</sup>, and Lindi Jiang<sup>4</sup>

**ABSTRACT. Objective.** To investigate the characteristics of patients with Takayasu arteritis (TA)-related renal artery stenosis and identify the predictors of medium-term adverse outcomes.

**Methods.** Data for 567 patients registered in the East China Takayasu arteritis cohort, a large prospective observational cohort, up to April 30, 2019, were retrospectively analyzed.

**Results.** Renal artery stenosis was confirmed in 172/567 (30.34%) patients, with left renal artery involvement seen in 73/172 (42.44%) patients. Renal insufficiency at presentation (HR 2.37, 95% CI 1.76–15.83,  $P = 0.03$ ), bilateral renal artery involvement (HR 6.95, 95% CI 1.18–21.55,  $P = 0.01$ ), and severe stenosis ( $> 75\%$ ; HR 4.75, 95% CI 1.08–11.33,  $P = 0.05$ ) were predictors of adverse outcomes. A matrix model constructed using 3 variables (renal function, stenosis severity, and bilateral renal artery involvement) could identify 3 risk groups. Revascularization was performed for 46 out of 172 (26.74%) patients. Patients without preoperative treatment had higher rate of restenosis (41.46% vs 16.67%,  $P < 0.01$ ) and worsening hypertension (25.93% vs. 10.53%,  $P < 0.01$ ) after the procedure. Nonreceipt of preoperative treatment (HR 6.5, 95% CI 1.77–32.98,  $P = 0.04$ ) and active disease at revascularization (HR 4.21, 95% CI 2.01–21.44,  $P = 0.04$ ) were independent predictors of adverse outcomes after revascularization.

**Conclusion.** Patients with TA-associated renal artery stenosis and uncontrolled or worsening hypertension or/and renal function may benefit from revascularization. Those who have received preoperative treatment may have more favorable revascularization outcomes. Prognosis appears to be poorer for patients with renal insufficiency at presentation, bilateral artery involvement, and severe stenosis.

*Key Indexing Terms:* adverse outcome, renal artery, revascularization, Takayasu arteritis

Takayasu arteritis (TA) is a chronic, large vessel vasculitis that primarily affects the aorta and its main branches<sup>1,2,3</sup>. The incidence of renal artery stenosis in TA is 20–60%, according to previous reports<sup>4,5,6</sup>. In patients under the age of 40 years, TA is responsible for 60.5% of cases of renal artery stenosis<sup>7</sup> and, among Asian patients with TA, almost half have renal artery involvement<sup>8</sup>. Renal artery stenosis can cause refractory hypertension, renal function disturbance, and premature death<sup>8,9,10</sup>. Early recognition and treatment of TA-related renal artery stenosis could help in preventing long-term adverse outcomes.

Treatment for TA-related renal artery stenosis includes pharmacotherapy and revascularization procedures. Glucocorticoids, immunosuppressants, and biological agents are used to control systemic and vascular inflammation, and prevent disease progression and organ damage<sup>11,12</sup>, whereas antihypertensive drugs are used to control blood pressure and prevent ischemic symptoms. Revascularization procedures may be needed to treat severe stenosis, malignant hypertension, or persistent refractory hypertension<sup>13,14</sup>. The results of vascular interventions for TA have not been consistent in previous studies, with some authors reporting a high rate of restenosis and others demonstrating good long-term arterial patency after treatment<sup>15,16,17</sup>. A major limitation of these earlier studies was that they did not evaluate how pharmacotherapy influenced the long-term outcomes of vascular interventions<sup>15,16,17</sup>.

The specific characteristics of patients with TA-related renal artery stenosis, the effect of revascularization procedures on prognosis, and the risk factors for adverse outcomes after the vascular intervention have not been fully investigated in Chinese populations. This study was designed to investigate (1) the characteristics of Chinese patients with TA-related renal artery stenosis, (2) the predictors of medium-term adverse outcomes in these patients, and (3) the predictors of adverse outcomes in the subgroup undergoing revascularization procedures.

*This study was sponsored by the National Natural Science Foundation of China (NSFC 81601398; NSFC 81771730).*

<sup>1</sup>Y. Sun, PhD, X. Dai, PhD, L. Ma, PhD, Y. Yan, PhD, Department of Rheumatology, Zhongshan Hospital, Fudan University; <sup>2</sup>P. Lv, PhD, J. Lin, PhD, Department of Radiology, Zhongshan Hospital, Fudan University; <sup>3</sup>Z. Dong, PhD, Department of Vascular Surgery, Zhongshan Hospital, Fudan University; <sup>4</sup>L. Jiang, MD, PhD, Department of Rheumatology, Zhongshan Hospital, Fudan University, and Center of Evidence-based Medicine, Fudan University, Shanghai, China.

Address correspondence to Dr. Lindi Jiang, PhD, MD, 180 Fenglin Road, Department of Rheumatology, Zhongshan Hospital, Fudan University, Shanghai 200032, P. R. China. Email: zsh-rheum@hotmail.com.

Accepted for publication April 21, 2020.

Personal non-commercial use only. The Journal of Rheumatology Copyright © 2020. All rights reserved.

## MATERIALS AND METHODS

**Patients.** This study was based on the East China Takayasu arteritis (ECTA) cohort, a prospectively maintained observational cohort. The ECTA (NCT03893136) was established in 2010 in our center, Zhongshan Hospital, which is a tertiary care hospital affiliated to Fudan University, Shanghai, China. For this retrospective study, we included all 567 patients registered in the ECTA up to April 30, 2019. All patients had been diagnosed with TA by rheumatologists using the 1990 American College of Rheumatology criteria<sup>18</sup>. The diagnoses were confirmed by whole-body enhanced magnetic resonance angiography (MRA), computed tomographic angiography (CTA), or vascular ultrasound (if angiography could not be performed because of allergy to iodine or other contraindications).

This study was performed in accordance with the tenets of the Helsinki Declaration and its amendments. The study protocol was approved by the Ethics Review Board of Zhongshan Hospital (B2013-115). Written informed consent was obtained from all patients.

**Medications.** At our center, medical therapy for TA has 2 phases: an induction phase and a maintenance phase. In the induction phase, oral prednisone is started at a dose of 0.8–1.0 mg/kg/day; after 4 weeks, the dose is tapered gradually over 5 months to a maintenance dose of 0.1–0.2 mg/kg/day. Along with prednisolone (PSL), an immunosuppressant [cyclophosphamide (CYC), methotrexate (MTX), azathioprine (AZA), leflunomide (LEF), or mycophenolate mofetil (MMF)] or a biological agent is also administered; the choice of immunosuppressant versus biological agent is at the physician's discretion. The dosages used are as follows: CYC, 0.5–0.75 g/m<sup>2</sup> (usually 0.8 g) intravenously every 4 weeks; MTX, 10–15 mg/week orally; AZA, 50–100 mg/day orally; LEF, 10–20 mg/day orally; and MMF, 1–2 g/day orally. Induction treatment lasts for 6 months. If active disease is still present at the end of 6 months, the PSL dose is adjusted and a change of the immunosuppressant drug is considered. Maintenance therapy is with MTX (10–15 mg/week orally), AZA (25–50 mg/day, orally), LEF (10–20 mg/day, orally), or MMF (1–1.5 g/day, orally).

Antihypertensive drugs are used to control blood pressure, with combinations of 2 or more drugs used when necessary. The drugs include calcium channel antagonists, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers,  $\beta$ -blockers,  $\alpha$ -blockers, diuretics, and others (e.g., clonidine).

**Disease activity assessment and follow-up.** Data recorded up to April 30, 2019, were collected for analysis. Demographic factors, clinical characteristics, laboratory findings, imaging features, and follow-up data were noted. Estimated glomerular filtration rate (eGFR) was calculated using the chronic kidney disease epidemiology collaboration equation<sup>19</sup>. Follow-up was conducted once a month during the induction period, and once every 3 months during the maintenance period. MRA or CTA was performed every 6 months to assess disease progression. Radioisotope renography was performed to evaluate renal dysfunction if necessary.

Disease activity was assessed using Kerr criteria<sup>20</sup>, which include the following: (1) systemic symptoms (not due to other causes such as infection, tumor and so on); (2) erythrocyte sedimentation rate; (3) vascular ischemic symptoms or signs (e.g., weak pulse or pulselessness, vascular bruits, or asymmetric blood pressure); and (4) positive imaging results. Appearance of new symptoms or worsening of 2 or more criteria indicates active disease.

**Definition of adverse outcomes.** Renal insufficiency was defined as serum creatinine  $\geq 130$   $\mu$ mol/L or eGFR  $\leq 60$  mL/min. Hypertension was defined as blood pressure  $\geq 140/90$  mmHg. Refractory hypertension was defined as blood pressure  $\geq 160/90$  mmHg despite maximal doses of 3 antihypertensive drugs.

Severity of renal artery stenosis was categorized as  $< 50\%$ , 50–75%, or  $> 75\%$  on MRA or CTA, as described in a previous study<sup>21</sup>.

Adverse outcomes for patients with TA-related renal artery stenosis included (1) persistent renal insufficiency at 6 months after diagnosis, or

deterioration of renal function ( $\geq 20\%$  increase in creatinine concentrations or  $\geq 20\%$  decrease in eGFR); (2) persistent refractory hypertension at 6 months or malignant hypertension; (3) congestive heart failure; and (4) TA-related death (e.g., death caused by severe arterial stenosis or aortic dissection). Adverse outcomes after renal artery revascularization procedures included (1) restenosis, (2)  $\geq 20\%$  increase in blood pressure after the procedure, (3)  $\geq 20\%$  deterioration of renal function after the procedure, and (4) TA-related death.

**Statistical analysis.** Categorical variables were summarized as counts and percentages and compared between groups using the chi-square test. Continuous variables were summarized as means  $\pm$  SD or as medians with IQR, depending on the normality of the distribution, and compared using the *t* test, Wilcoxon test, or Mann-Whitney test. Univariate logistic regression analysis was performed to examine the association of baseline factors with outcomes. Factors significantly associated (at  $P < 0.10$ ) with poor outcome were entered into a Cox proportional hazards regression model to identify the independent predictors of adverse outcomes, and the HR and 95% CI were calculated. Using these results, a risk-prediction matrix was built that could be used to stratify patients according to risk of adverse outcomes. The ability of the model to predict adverse outcomes was assessed using receiver-operating characteristic (ROC) curve analysis. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated. Statistical analysis was performed using SPSS 22.0 (IBM Corp.). Two-sided  $P < 0.05$  indicated statistical significance.

## RESULTS

**Patient characteristics.** A total of 567 TA patients were included in this study. Table 1 presents the characteristics of the patients. Median age at disease onset was 29 (22–38) years, and median age at diagnosis was 31 (22–38) years. The majority of patients were female (455/567, 80.25%). According to the 1996 Numano classification system<sup>22</sup>, the most common type was type V (234/567, 41.79%), followed by type II (147/567, 25.93%), type I (74/567, 13.05%), and type IV (63/567, 11.11%).

**Comparison of disease features between patients with and without renal artery involvement.** Renal artery involvement was confirmed in 172/567 (30.34%) patients. Bilateral renal artery involvement was observed in 55/172 (31.98%) patients. While 12/172 (6.98%) patients had only renal artery involvement, the rest also had involvement of other arteries, including left carotid artery (56/172, 32.56%), left subclavian artery (57/172, 33.14%), and abdominal aorta (51/172, 29.65%).

The group with renal artery involvement had a significantly lower proportion of female patients ( $P = 0.04$ ) and a significantly lower prevalence of systemic symptoms ( $P = 0.03$ ). The group had a significantly higher prevalence of hypertension ( $P = 0.02$ ), especially refractory hypertension ( $P < 0.01$ ), and a significantly higher prevalence of renal insufficiency ( $P = 0.03$ ; Table 1).

**Risk factors for medium-term adverse outcomes in TA-related renal artery stenosis.** The median follow-up period of patients with renal artery stenosis was 45 (3–78) months. During the follow-up, 46/172 (26.74%) patients suffered adverse outcomes: 17 patients had persistent refractory hypertension, 6 patients had malignant hypertension, 7 patients had persistent renal insufficiency, 4 patients had renal function deterioration, 7 patients had

Table 1. Comparison of clinical characteristics between Takayasu arteritis patients with and without renal artery stenosis.

	Total, N = 567	With Renal Artery Involvement, n = 172	Without Renal Artery Involvement, n = 395	P
<b>Demographic characteristics</b>				
Female	455 (80.25)	120 (69.77)	335 (93.31)	0.04
Age at disease onset, yrs, median (IQR)	29 (22–38)	27 (16–38)	30 (22–46)	0.34
Age at diagnosis, yrs, median (IQR)	31 (22–38)	30 (16–39)	32 (20–47)	0.29
<b>Clinical manifestations</b>				
Systemic symptoms	184 (32.45)	35 (20.35)	149 (37.72)	0.03
Ischemia symptoms	209 (36.86)	47 (27.33)	162 (41.01)	0.11
<b>Physical signs</b>				
Pulselessness	118 (19.76)	29 (16.86)	89 (22.53)	0.47
Vascular murmur	103 (18.17)	25 (14.53)	78 (19.75)	0.51
Hypertension at presentation	199 (35.09)	85 (49.42)	114 (28.86)	0.02
Refractory hypertension	95 (16.75)	51 (29.65)	44 (11.14)	< 0.01
Renal insufficiency	67 (11.82)	31 (18.02)	36 (10.03)	0.03
<b>Treatments at presentation</b>				
GC, mg/d, median dose (IQR)	37.5 (12.5–55)	35 (15–55)	42.5 (22.5–55)	0.71
CYC	309 (54.40)	87 (50.58)	222 (61.84)	0.53
MTX	87 (15.34)	26 (15.12)	61 (16.99)	0.77
LEF	74 (13.05)	25 (14.53)	49 (13.65)	0.51
MMF	42 (7.41)	9 (5.23)	14 (3.89)	0.04
AZA	23 (4.06)	14 (8.14)	28 (7.79)	0.48
Biological agents*	19 (3.35)	7 (4.07)	12 (3.34)	0.63

Values are n (%) unless otherwise specified. \* Biological agents included tumor necrosis factor antagonist, rituximab, and tocilizumab. AZA: azathioprine; CYC: cyclophosphamide; GC: glucocorticoid; MTX: methotrexate; LEF: leflunomide; MMF: mycophenolate mofetil.

congestive heart failure, and 5 patients died due to TA-related causes (2 congestive heart failure, 1 malignant arrhythmia, 1 aortic dissection, and 1 acute myocardial infarction).

Patients with renal artery stenosis could be separated into 3 groups according to the severity of renal artery stenosis: < 50% stenosis (n = 47), 50–75% stenosis (n = 51), and > 75% stenosis (n = 52). Table 2 presents a comparison of the characteristics of these 3 groups.

Supplementary Table 1 (available with the online version of this article) presents the results of logistic regression analysis of baseline factors. Cox proportional hazards regression analysis showed that renal insufficiency at presentation (HR 2.37, 95% CI 1.76–15.83,  $P = 0.03$ ), bilateral renal artery involvement (HR 6.95, 95% CI 1.18–21.55,  $P = 0.01$ ), and severe (> 75%) stenosis (HR 4.75, 95% CI 1.08–11.33,  $P = 0.05$ ) were independent predictors of adverse outcomes (data not shown).

Using these variables (i.e., baseline renal function, severity of renal artery stenosis, and presence of bilateral renal artery involvement), we built a risk-prediction matrix that could be used to stratify patients into different risk groups (Figure 1A). ROC analysis showed satisfactory performance of the model: 89% sensitivity, 71% specificity, 82% PPV, and 88% NPV for predicting risk of adverse outcomes.

*Comparisons of characteristics of patients with and without*

*revascularization.* A total of 46/172 (26.74%) patients underwent revascularization procedures. Table 3 presents data for patients with and without revascularization. The revascularization group had significantly higher proportions of patients with renal insufficiency ( $P = 0.03$ ), hypertension ( $P = 0.04$ ), especially refractory hypertension ( $P < 0.01$ ), and severe stenosis ( $P < 0.01$ ).

*Effect of preoperative therapy on outcomes of renal artery revascularization.* A total of 65 renal artery revascularization procedures were performed in 46 patients (1.41 per person, range: 1–4). The procedures included percutaneous transluminal angioplasty (PTA; 40/65, 61.54%), stent implantation (16/65, 24.62%), autotransplantation (2/65, 3.08%), bypass surgery (3/65, 4.62%), and nephrectomy (4/65, 6.16%). The median follow-up after revascularization was for 34 (3–52) months.

According to whether or not glucocorticoids and immunosuppressant drugs were used, the patients undergoing revascularization procedures could be separated into 2 groups: the preoperative therapy group (n = 24) and the nonpreoperative therapy group (n = 41). In the preoperative therapy group, median duration of preoperative therapy was for 9 (IQR 1–15) months. In the nonpreoperative therapy group, all 41 patients underwent revascularization procedures before definite diagnosis of TA; the procedures were performed to control blood

Table 2. Comparisons of clinical characteristics between patients with different degrees of renal artery stenosis.

	< 50% Stenosis, n = 47	50–75% Stenosis, n = 51	> 75% Stenosis, n = 74	P
Demographic characteristics				
Female	33 (70.21)	36 (70.59)	51 (68.92)	0.47
Clinical manifestations				
Systemic symptoms	8 (17.02)	9 (17.64)	18 (24.32)	0.04
Ischemia symptoms	11 (23.40)	10 (19.61)	16 (21.62)	0.31
Physical signs				
Pulselessness	8 (17.02)	7 (13.73)	14 (18.92)	0.48
Vascular murmur	9 (19.15)	8 (15.69)	8 (10.81)	0.32
Hypertension at presentation	12 (25.53)	21 (41.18)	52 (70.27)	< 0.01
Refractory hypertension at presentation				
	8 (17.02)	12 (23.53)	31 (41.89)	0.02
Renal insufficiency at presentation	5 (10.64)	8 (15.69)	21 (28.38)	0.04
Treatments at presentation				
GC, mg/d, median dose (IQR)	25 (20–35)	30 (15–45)	40 (35–55)	0.03
Immunosuppressant*	38 (80.85)	49 (96.08)	74 (100)	0.81
Biological agents†	1 (2.13)	2 (3.92)	4 (5.41)	0.07
Revascularization	0	5 (9.80)	41 (55.41)	< 0.01
Adverse outcomes	10 (21.28)	13 (25.49)	23 (31.08)	0.05

Values are n (%) unless otherwise specified. \* Immunosuppressants included cyclophosphamide, methotrexate, leflunomide, mycophenolate mofetil, azathioprine. † Biological agents included tumor necrosis factor inhibitor, rituximab, tocilizumab. GC: glucocorticoid.




Figure 1. (A) Matrix model for predicting risk of adverse outcomes in TA patients with renal artery stenosis. Based on baseline renal function, renal artery stenosis severity, and presence of bilateral involvement, patients could be separated into 3 risk groups: high risk (red, > 50%), moderate risk (green, between 30–50%), and low risk (yellow, < 30%). (B) Matrix model for predicting risk of adverse outcomes after vascular intervention. Based on renal artery stenosis severity, receipt of preoperative treatment, and disease activity at time of intervention, patients could be separated into 3 risk groups: high risk (red, > 25%), moderate risk (green, between 10–25%), and low risk (yellow, < 10%). TA: Takayasu arteritis; NA: not applicable.

Table 3. Comparisons of disease features between patients with and without revascularization.

	Patients With Revascularization, n = 46	Patients Without Revascularization, n = 126	P
<b>Clinical features</b>			
Sex, female	36 (78.23)	84 (66.67)	0.14
Age at diagnosis, yrs, median (IQR)	28 (17–36)	34 (22–37)	0.02
Delay in diagnosis > 1 yr	24 (52.17)	56 (44.44)	0.32
Hypertension	46 (100)	39 (30.95)	< 0.01
Refractory hypertension at presentation	29 (63.04)	21 (16.67)	< 0.01
Renal insufficiency at presentation	12 (26.09)	19 (15.08)	0.03
<b>Renal artery involvements</b>			
Bilateral involvement	17 (36.96)	36 (30.16)	0.32
Severity of stenosis			< 0.01
< 50%	0	33 (26.19)	
50–75%	11 (23.91)	59 (46.83)	0.03
> 75%	35 (76.09)	34 (26.98)	< 0.01
<b>Treatments for hypertension</b>			
CCB	37 (80.43)	31 (79.49)	0.44
β-blocker	29 (63.04)	30 (76.92)	0.39
ACEI/ARB*	3 (6.52)	5 (12.82)	0.03
Diuretic	16 (41.03)	6 (15.38)	0.02
≥ 4-drug combination	16 (61.54)	11 (22.92)	< 0.01

Values are n (%) unless otherwise specified. \* ARB did not include those with unilateral involvement. ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; CCB: calcium channel blocker.

pressure or manage acute ischemic events. In both groups, blood pressure decreased immediately after revascularization. However, at 6 months after the procedure, the nonpreoperative therapy group showed a significant increase in blood pressure (Figures 2C,D). A similar pattern was observed in the changes in renal function in the 2 groups (Figures 2A,B). Restenosis rate was significantly higher in the nonpreoperative therapy group (41.46% vs 16.67%,  $P < 0.01$ ) during the first 2 years after revascularization (Figure 3A; HR 2.37, 95% CI 1.76–15.83,  $P = 0.03$ ).

**Risk factors for adverse outcomes after renal artery revascularization.** The risk factors for adverse outcomes after renal artery revascularization included renal insufficiency at presentation (OR 1.87, 95% CI 1.12–21.34,  $P = 0.04$ ), refractory hypertension at presentation (OR 2.06, 95% CI 1.07–19.44,  $P = 0.03$ ), active disease at the time of surgery (OR 4.06, 95% CI 1.42–21.78,  $P = 0.03$ ), and nonreceipt of preoperative therapy (OR 7.4, 95% CI 2.05–47.31,  $P = 0.03$ ).

In Cox proportional hazards regression analysis, the independent predictors of adverse outcome after revascularization were nonreceipt of preoperative therapy (HR 6.5, 95% CI 1.77–32.98,  $P = 0.04$ ; Figure 3B), active disease at the time of surgery (HR 4.21, 95% CI 2.01–21.44,  $P = 0.04$ ), and severe stenosis (HR 1.98, 95% CI 1.18–17.32).

Using these variables (i.e., nonreceipt of preoperative treatment, presence of active disease at the time of surgery, and severity of stenosis), we built a risk-prediction matrix that could be used to stratify patients into different risk groups (Figure 1B).

ROC analysis showed satisfactory performance of the model: 87% sensitivity, 69% specificity, 78% PPV, and 84% NPV for predicting risk of adverse outcomes after revascularization.

## DISCUSSION

This study was performed to determine the characteristics of Chinese patients with TA with renal artery involvement and to identify the predictors of medium-term adverse outcomes. To our knowledge, this is the largest cohort of patients with TA-related renal artery stenosis.

In this study, renal artery involvement was seen in 30.34% patients, which is notably lower than the 48.92% reported in another Chinese study<sup>8</sup>. Consistent with the earlier study, we found hypertension, especially refractory hypertension, and renal insufficiency to be significantly more common in patients with renal artery involvement. In our sample, systemic symptoms were uncommon in patients with renal artery involvement; this is an important finding since it suggests that diagnosis of TA may sometimes be delayed or missed. Thus, in patients with hypertension, especially in those younger than 40 years, an etiological diagnosis is essential, and TA-related renal artery stenosis should be ruled out.

Medium-term outcomes in patients with TA-related renal artery stenosis have been previously described in Korean<sup>10</sup> and white<sup>23</sup> populations. In the Korean study, bilateral lesions and renal functional impairment at presentation were significant adverse prognostic factors; this result is concordant with our findings. However, in the white population, medium-term




Figure 2. (A–B) Change in renal function (serum creatinine level and eGFR) in patients with and without preoperative treatment before vascular intervention. (C–D) Change in blood pressure of patients with and without preoperative treatment before vascular intervention. eGFR: estimated glomerular filtration rate.




Figure 3. (A) Cumulative incidence of renal artery restenosis in patients with and without preoperative treatment before vascular intervention. (B) Kaplan-Meier curves of survival without adverse outcome in patients with and without preoperative treatment before vascular intervention.

nonrenal and renal outcomes were favorable; no patient experienced endstage renal disease or died. The different results in the latter study may be related to the relatively small sample size and short follow-up period, in addition to the ethnicity of the enrolled patients.

PTA was the most commonly used revascularization procedure (61.54%) in our sample; this is consistent with earlier reports<sup>24,25,26</sup>. Nonreceipt of preoperative treatments and active disease at the time of vascular surgery were the most important risk factors for long-term adverse outcomes after revascularization. TA-related renal artery stenosis is a kind of inflammatory vasculitis, and previous studies have shown that active vascular inflammation may be associated with a higher rate of complications and restenosis after revascularization<sup>27,28</sup>. There are still no guidelines on how to select the best time for revascularization in TA-related stenosis. While effective preoperative medication may improve outcomes, the optimal preoperative treatment duration remains to be determined.

We found that hypertension caused by TA-related renal artery stenosis might be controlled with the combination of

renal artery revascularization and medication. Three patients in our cohort stopped antihypertensive drugs after the renal artery revascularization (Supplementary Table 2, available with the online version of this article); their blood pressure was normal for 6–24 months after the procedure. Randomized controlled trials are needed to confirm the long-term effects and safety of the combination of medication and revascularization.

Our study has several strengths. First, the sample size is much larger than that of previous studies. Second, in addition to reporting the outcomes of patients with TA-related renal artery stenosis, we also identify the risk factors for adverse outcomes. The matrix model that we propose (Figure 1A) can be conveniently applied in clinical practice to identify high-risk patients. We also analyze the outcomes and risk of adverse outcomes for the subgroup of patients undergoing revascularization procedures.

We recognize several limitations in our research. First, the follow-up duration was short. Second, there is a possibility that some patients in this study may have had fibromuscular dysplasia (FMD). FMD is a noninflammatory and nonatherosclerotic

vascular disease that mainly involves the renal and carotid arteries. The typical imaging characteristic of FMD is the string-of-beads sign on digital subtraction angiography, CTA, or MRA. A few cases with atypical imaging features may have been misdiagnosed.

In conclusion, our study demonstrated renal artery involvement in 30% of Chinese patients with TA. Patients with uncontrolled or worsening hypertension or/and renal function may benefit from revascularization. Preoperative treatment appears to improve revascularization outcomes, though prognosis may be poorer for patients with renal insufficiency at presentation, bilateral artery involvement, and severe stenosis.

## ONLINE SUPPLEMENT

Supplementary material accompanies the online version of this article.

## REFERENCES

1. Johnston SL, Lock RJ, Gompels MM. Takayasu arteritis: a review. *J Clin Pathol* 2002;55:481-6.
2. Watanabe Y, Miyata T, Tanemoto K. Current clinical features of new patients with Takayasu arteritis observed from cross-country research in Japan: age and sex specificity. *Circulation* 2015;132:1701-9.
3. Yilmaz N, Can M, Oner FA, Kalfa M, Emmungil H, Karadag O, et al. Impaired quality of life, disability and mental health in Takayasu's arteritis. *Rheumatology* 2013;52:1898-904.
4. Maksimowicz-McKinnon K, Clark TM, Hoffman GS. Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. *Arthritis Rheum* 2007;56:1000-9.
5. Weaver FA, Kumar SR, Yellin AE, Anderson S, Hood DB, Rowe VL, et al. Renal revascularization in Takayasu arteritis-induced renal artery stenosis. *J Vasc Surg* 2004;39:749-57.
6. Sharma S, Gupta A. Visceral artery interventions in Takayasu's arteritis. *Semin Intervent Radiol* 2009;26:233-44.
7. Peng M, Jiang XJ, Dong H, Zou YB, Zhang HM, Song L, et al. Etiology of renal artery stenosis in 2047 patients: a single-center retrospective analysis during a 15-year period in China. *J Hum Hypertens* 2016;30:124-8.
8. Chen Z, Li J, Yang Y, Li H, Zhao J, Sun F, et al. The renal artery is involved in Chinese Takayasu's arteritis patients. *Kidney Int* 2018;93:245-51.
9. Anderson GH Jr, Blakeman N, Streeten DH. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. *J Hypertens* 1994;12:609-15.
10. Hong S, Ghang B, Kim YG, Lee CK, Yoo B. Long term outcomes of renal artery involvement in Takayasu arteritis. *J Rheumatol* 2017;44:466-72.
11. Goel R, Danada D, Joseph G, Ravindran R, Kumar S, Jayaseeian V, et al. Long-term outcome of 251 patients with Takayasu arteritis on combination immunosuppressant therapy: single centre experience from a large tertiary care teaching hospital in Southern India. *Semin Arthritis Rheum* 2018;47:718-26.
12. Goel R, Danda D, Kumar S, Joseph G. Rapid control of disease activity by tocilizumab in 10 'difficult-to-treat' cases of Takayasu arteritis. *Int J Rheum Dis* 2013;16:754-61.
13. Jung JH, Lee YH, Song GG, Jeong HS, Kim JH, Choi SJ. Endovascular versus open surgical intervention in patients with Takayasu's arteritis: a meta-analysis. *Eur J Vasc Endovasc Surg* 2018;55:888-99.
14. Jeong HS, Jung JH, Song GG, Choi SJ, Hong SJ. Endovascular balloon angioplasty versus stenting in patients with Takayasu arteritis: a meta-analysis. *Medicine* 2017;96:e7558.
15. Sharma BK, Jain S, Bali HK, Jain A, Kumari S. A follow-up study of balloon angioplasty and de-novo stenting in Takayasu arteritis. *Int J Cardiol* 2000;75 Suppl 1:S147-52.
16. Park HS, Do YS, Park KB, Kim DK, Choo SW, Shin SW, et al. Long term results of endovascular treatment in renal arterial stenosis from Takayasu arteritis: angioplasty versus stent placement. *Eur J Radiol* 2013;82:1913-8.
17. Ham SW, Kumar SR, Wang BR, Rowe VL, Weaver FA. Late outcomes of endovascular and open revascularization for nonatherosclerotic renal artery disease. *Arch Surg* 2010;145:832-9.
18. Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, Edworthy SM, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. *Arthritis Rheum* 1990;33:1129-34.
19. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. *Ann Intern Med* 2009;150:604-12.
20. Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, et al. Takayasu arteritis. *Ann Intern Med* 1994;120:919-29.
21. Jiang L, Li D, Yan F, Dai X, Li Y, Ma L. Evaluation of Takayasu arteritis activity by delayed contrast-enhanced magnetic resonance imaging. *Int J Cardiol* 2012;155:262-7.
22. Hata A, Noda M, Moriwaki R, Numano F. Angiographic findings of Takayasu arteritis: new classification. *Int J Cardiol* 1996;54:S155-63.
23. Baldwin C, Mohammad AJ, Cousins C, Carette S, Pagnoux C, Jayne D. Long-term outcomes of patients with Takayasu arteritis and renal artery involvement: a cohort study. *Rheumatol Adv Pract* 2018;2:rky026.
24. Peng M, Ji W, Jiang X, Dong H, Zou Y, Song L, et al. Selective stent placement versus balloon angioplasty for renovascular hypertension caused by Takayasu arteritis: two-year results. *Int J Cardiol* 2016;205:117-23.
25. Kinjo H, Kafa A. The results of treatment in renal artery stenosis due to Takayasu disease: comparison between surgery, angioplasty, and stenting. A monocentric retrospective study. *G Chir* 2015;36:161-7.
26. Yamamoto T, Shirai K, Okamura K, Urata H. Two years efficacy of paclitaxel-coated balloon dilation for in-stent renal artery restenosis due to Takayasu arteritis. *Am J Case Rep* 2019;20:1089-93.
27. Park MC, Lee SW, Park YB, Lee SK, Choi D, Shim WH. Post-interventional immunosuppressive treatment and vascular restenosis in Takayasu's arteritis. *Rheumatology* 2006;45:600-5.
28. Kim SM, Jung IM, Han A, Min S-I, Lee T, Ha J, et al. Surgical treatment of middle aortic syndrome with Takayasu arteritis or midaortic dysplastic syndrome. *Eur J Vasc Endovasc Surg* 2015;50:206-12.